Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of DA-2811 vs Forxiga in Healthy Subjects
NCT04473417Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Aug 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-2811-R in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Dong-A ST. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration and Maximum observed plasma concentration. Started Aug 2020; status: completed.
02
Drugs
DA-2811-R
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04473417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04473417.